Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sat Kartar Life
Quarter-by-quarter operating performance
Financials of Sat Kartar Life
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 52 | 83 | 128 | 163 | 194 |
| Expenses + | 49 | 78 | 118 | 149 | 169 |
| Operating Profit | 3 | 5 | 10 | 14 | 25 |
| OPM % | 5% | 6% | 8% | 9% | 13% |
| Other Income + | 0 | 0 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 2 | 3 | 9 | 13 | 23 |
| Tax % | 7% | 27% | 27% | 25% | 26% |
| Net Profit + | 1 | 3 | 6 | 10 | 17 |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 | 10.96 |
| Dividend Payout % | 0% | 0% | 3% | 11% | 0% |
Financials of Sat Kartar Life
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 52 |
| Borrowings + | 8 | 4 | 2 | 6 | 2 |
| Other Liabilities + | 3 | 8 | 11 | 6 | 14 |
| Total Liabilities | 12 | 15 | 22 | 64 | 84 |
| Fixed Assets + | 5 | 4 | 8 | 7 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 |
| Other Assets + | 8 | 11 | 14 | 57 | 71 |
| Total Assets | 12 | 15 | 22 | 64 | 84 |
Financials of Sat Kartar Life
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 7 | -5 | 0 | ||
| Cash from Investing Activity + | -3 | -0 | -9 | ||
| Cash from Financing Activity + | -3 | 34 | -1 | ||
| Net Cash Flow | 2 | 28 | -9 | ||
| Free Cash Flow | 7 | -10 | -7 | ||
| CFO/OP | 98% | -13% | 26% |
Financials of Sat Kartar Life
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 | 26 |
| Inventory Days | 31 | 25 | 23 | 185 | 258 |
| Days Payable | 165 | 226 | 237 | 170 | 293 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 | -9 |
| Working Capital Days | 1 | -14 | -7 | 31 | 61 |
| ROCE % | 50% | 98% | 40% | 37% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…